

FINAL PROGRAMME


31 AUGUST - 4 SEPTEMBER
amsterdam
NETHERLANDS

w w w . e s c a r d i o . o r g

ESC CONGRESS 2013



Most scientific sessions, except satellite symposia, are arranged by topics in themed villages



Dear Cardiology friends and colleagues from around the world!

Welcome to ESC Congress 2013 in Amsterdam.
We have worked hard to bring you an exceptional, innovative and exciting congress.

Exceptional because this is the largest international cardiology congress with faculty and abstracts from 82 countries, 33 joint sessions with sister Societies and with participants from all parts of the world. Despite the overall size, ESC Congress has a manageable scale thanks to related topics clustered together in "Villages".

Innovative because we have newly designed interactive sessions in the Hub, Rapid-Fire presentations followed by face to face discussions, Challenge the Experts sessions, Meet the Legends and much more...

Exciting because you can design an electronic programme tailored to your own interests, your educational needs and the breaking news in your field.
Visit escardio.org/ESC2013 to browse all the web resources including the ESC 2013 Mobile App.

The spotlight of ESC Congress is the "**Heart Interacting with Systemic Organs**", and we have much to learn from related specialties. Cross conventional specialty sessions will provide innovative approaches to make the next set of advances in understanding and patient care.

We have more Hot Lines than ever before and important **new ESC Clinical Practice Guidelines in Hypertension, Stable Angina, Pacing and Diabetes**.

Come to the Focus Sessions and learn how new developments and guidelines can affect real clinical cases. If you are in training or in research you cannot miss the ESC Cardiologists of Tomorrow sessions, new ESC Scientists of Tomorrow, and Science in Practice sessions (right within the clinical topics in the villages).

Remember the exhibition, the satellite symposia and **new developments from industry partners**. We acknowledge their ongoing support.

ESC Congress is **designed for the future**: Key sessions will be shown live from Amsterdam on the website and we have developed the ESC Congress 365 platform with educational "tracks" accessible locally and all year long.



Panos E Vardas FESC, President
European Society of Cardiology
2012 - 2014



Keith A A Fox, FESC, Chairperson
Congress Programme Committee
2012 - 2014

and all the ESC members of
Congress Programme Committee

The **Inaugural Session** on Saturday 31 August is a key introduction to the congress and it has some surprises in store – don't miss it!

We are delighted that you have chosen to be part of ESC Congress and help shape the future of cardiology!

We hope you will enjoy the hospitality of the City of Amsterdam and we know that you will remember being part of ESC Congress 2013!



ESC CONGRESS COMMITTEE

P E Vardas FESC (Heraklion, GR) – ESC President
K A A Fox FESC (Edinburgh, GB) – Chairperson Congress Programme Committee (CPC)

ESC CONGRESS PROGRAMME COMMITTEE 2013

The Scientific Programme has been prepared by the ESC Congress Programme Committee in close collaboration with the ESC Working Groups, Associations, Councils and ad hocs according to the nine following topic groups.

Most scientific sessions, except satellite symposia, are arranged by topics in themed villages. You will also find the scientific highlights of the 9 main topics of ESC Congress 2013 in Central Village.

CENTRAL VILLAGE: BASIC SCIENCE

A R Pries FESC (Berlin, DE) – Coordinator
L Badimon FESC (Barcelona, ES)
F Di Lisa (Padua, IT)
T Eschenhagen FESC (Hamburg, DE) – International Society for Heart Research (ISHR)
D Hilfiker-Kleiner FESC (Hannover, DE)
J D Pearson FESC (London, GB)
L Tokgozogl FESC (Ankara, TR) – European Atherosclerosis Society (EAS)

VILLAGE 1: ARRHYTHMIAS - PACING - RESYNCHRONISATION

C Leclercq FESC (Rennes, FR) – Coordinator
M Brignole FESC (Lavagna, IT)
H Burri (Geneva, CH)
I Fernandez Lozano FESC (Madrid, ES) – European Heart Rhythm Association (EHRA)
G Hindricks FESC (Leipzig, DE)
J Kautzner FESC (Prague, CZ)

VILLAGE 2: HEART FAILURE – LEFT VENTRICULAR DYSFUNCTION

G S Filippatos FESC (Athens, GR) – Coordinator
S D Anker FESC (Berlin, DE) – Heart Failure Association (HFA)
M Komajda FESC (Paris, FR) – ESC Past President
M Lainscak FESC (Golnik, SI)
J L Lopez-Sendon FESC (Madrid, ES)
L S Maier FESC (Gottingen, DE)
T A McDonagh FESC (London, GB)
M F Piepoli FESC (Piacenza, IT)



VILLAGE 3: ISCHAEMIA – CORONARY ARTERY DISEASE - ACUTE CARDIAC CARE

S D Kristensen	FESC (Aarhus, DK) – Coordinator
F Andreotti	(Rome, IT)
S C Clarke	FESC (Cambridge, GB)
D Erlinge	FESC (Lund, SE)
R A Harrington	FESC (Stanford, US) – American Heart Association (AHA)
U Landmesser	FESC (Zurich, CH)
S Price	FESC (London, GB) – Acute Cardiovascular Care Association (ACCA)
R F Storey	FESC (Sheffield, GB)
C J M Vrints	FESC (Edegem, BE) – Acute Cardiovascular Care Association (ACCA)

VILLAGE 4: PREVENTION - REHABILITATION - SPORTS - NURSING

V Conraads	FESC (Edegem, BE) – Coordinator
M C Deaton	FESC (Manchester, GB) – Coordinator
D Gaita	FESC (Timisoara, RO)
U Laufs	(Homburg, DE) – European Association for Cardiovascular Prevention and Rehabilitation (EACPR)
	(Salzburg, AT)
J Niebauer	(Copenhagen, DK)
E Prescott	FESC (Chapel Hill, US) – World Heart Federation (WHF)
S Smith	FESC (Sopot, PL)
T Zdrojewski	

VILLAGE 5: INTERVENTIONS - PERIPHERAL CIRCULATION - STROKE - SURGERY

J-P Collet	FESC (Paris, FR) – Coordinator
V Aboyans	FESC (Limoges, FR)
D Dudek	FESC (Krakow, PL)
N S Kleiman	(Houston, US) – American College of Cardiology (ACC)
H K Najm	FESC (Riyadh, SA) – Saudi Heart Association (SHA)
Y Ozaki	FESC (Toyoake, JP) – Japanese Circulation Society (JCS)
L A Piva e Mattos	FESC (Recife, BR) – Brazilian Society of Cardiology (BSC)
M Roffi	FESC (Geneva, CH) – European Association of Percutaneous Cardiovascular Interventions (EAPCI)
K H Sim	FESC (Kuching, MY) – Asian Pacific Society of Cardiology (APSC)
M Sousa Uva	FESC (Lisbon, PT)
J M Ten Berg	FESC (Nieuwegein, NL)
M Valgimigli	FESC (Ferrara, IT)



VILLAGE 6: VALVULAR DISEASE - PULMONARY CIRCULATION - MYOCARDIAL-PERICARDIAL DISEASE - CONGENITAL HEART DISEASE & PAEDIATRIC CARDIOLOGY

A Keren	FESC (Jerusalem, IL) - Coordinator
H Baumgartner	FESC (Muenster, DE)
A L P Caforio	FESC (Padua, IT)
N Galie	(Bologna, IT)
S A Qureshi	(London, GB) - Association for European Paediatric Cardiology (AEPC)
R Rosenhek	FESC (Vienna, AT)
P Tornos Mas	FESC (Barcelona, ES)

VILLAGE 7: HYPERTENSION - PHARMA

F Ruschitzka	FESC (Zurich, CH) – Coordinator
M A Alonso Garcia	FESC (Madrid, ES)
D Atar	FESC (Oslo, NO)
M Dorobantu	FESC (Bucharest, RO)
E V Shlyakhto	FESC (St. Petersburg, RU)
S Taddei	FESC (Pisa, IT)
B Williams	FESC (London, GB)

VILLAGE 8: CARDIAC IMAGING - COMPUTERS

J L Zamorano Gomez	FESC (Madrid, ES) – Coordinator
L P Badano	FESC (Padua, IT) – European Association of Cardiovascular Imaging (EACVI)
G A Derumeaux	FESC (Bron, FR)
C Fernandez-Gofin Loban	FESC (Madrid, ES)
E Giannitsis	FESC (Heidelberg, DE)
D Neglia	FESC (Pisa, IT)
D J Pennell	FESC (London, GB)
F J Pinto	FESC (Lisbon, PT) – ESC President Elect
F E Rademakers	FESC (Leuven, BE)

VILLAGE 9: FOCUS SESSIONS

E Eeckhout	FESC (Lausanne, CH) – Coordinator
L Pierard	FESC (Liege, BE) – Coordinator
M Böhm	FESC (Homburg, DE) - Past CPC Chairperson
J-P Collet	FESC (Paris, FR)
V Conraads	FESC (Edegem, BE)
G A Derumeaux	FESC (Bron, FR)
P Tornos Mas	FESC (Barcelona, ES)
B Williams	FESC (London, GB)



WITH SPECIAL THANKS TO OUR AD HOC MEMBERS

G Baron Esquivias	FESC (Seville, ES)	Council for Cardiology Practice
J Bauersachs	FESC (Hannover, DE)	Working Group on Myocardial Function
C Brotons	(Barcelona, ES)	Council on Cardiovascular Primary Care
B Casadei	FESC (Oxford, GB)	Council on Basic Cardiovascular Science
P Charron	FESC (Paris, FR)	Working Group on Myocardial and Pericardial Diseases
R Cifkova	FESC (Prague, CZ)	Working Group on Hypertension and the Heart
V Falk	FESC (Zurich, CH)	Working Group on Cardiovascular Surgery
D Fitzsimons	NFESC (Belfast, GB)	Council on Cardiovascular Nursing and Allied Professions
M A Gomez Sanchez	FESC (Madrid, ES)	Working Group on Pulmonary Circulation and Right Ventricular Function
D J Hausenloy	FESC (London, GB)	Working Group on Cellular Biology of the Heart
P J Holm	FESC (Lund, SE)	Working Group on Grown-Up Congenital Heart Disease
R Kelly	(Marseille, FR)	Working Group on Development, Anatomy and Pathology
A N Kitsiou	FESC (Athens, GR)	Working Group on Nuclear Cardiology and Cardiac CT
K P Kjeldsen	(Copenhagen, DK)	Working Group on Cardiovascular Pharmacology and Drug Therapy
M Lombardi	FESC (Pisa, IT)	Working Group on Cardiovascular Magnetic Resonance
M Malik	FESC (Purley, GB)	Working Group on e-Cardiology
B D Prendergast	FESC (Oxford, GB)	Working Group on Valvular Heart Disease
C Vlachopoulos	FESC (Athens, GR)	Working Group on Peripheral Circulation
P Volders	FESC (Maastricht, NL)	Working Group on Cardiac Cellular Electrophysiology
C Weber	FESC (Munich, DE)	Working Group on Atherosclerosis and Vascular Biology

ESC CARDIOLOGISTS OF TOMORROW NUCLEUS

R Fontes Carvalho	(Porto, PT)
E A Jankowska	FESC (Wroclaw, PL)
M Pazdernik	(Prague, CZ)
J Poess	(Homburg, DE)
I Racz	(Debrecen, HU)
R C Vidal Perez	FESC (Santiago de Compostela, ES)
S Zuily	(Vandoeuvre les Nancy, FR)

GUIDELINES FOR INDUSTRY PARTICIPATION COMMITTEE

K A A Fox	FESC (Edinburgh, GB)
I Marti	(Allschwil, CH)
M Weimers	(Molndal, SE)
S Willemse	(Best, NL)
S Winter	(Erlangen, DE)

ESC PRESS COMMITTEE

K Huber	FESC (Vienna, AT) – Chairperson
L Badimon	FESC (Barcelona, ES)
M E Bertrand	FESC (Lambersart, FR)
H Darius	FESC (Berlin, DE)
J R Gonzalez Juanatey	FESC (Santiago de Compostela, ES)
S D Kristensen	FESC (Aarhus, DK)
J Perk	FESC (Oskarshamn, SE)
F Schiele	FESC (Besançon, FR)
J M Ten Berg	FESC (Nieuwegein, NL)
M Valgimigli	FESC (Ferrara, IT)
F W A Verheugt	FESC (Amsterdam, NL)



Welcome Letter	G1
ESC Congress Committees / Villages & main topics	G2

The European Society of Cardiology, your Community **G9**

ESC Board 2012 - 2014	G10
ESC General Assembly	G11
ESC in Brussels	G12
ESC Plaza & Membership	G13
ESC National Cardiac Societies	G14
ESC Fellowship	G15
ESC Cardiologists of Tomorrow	G19
Acute Cardiovascular Care Association (ACCA)	G20
European Association of Cardiovascular Imaging (EACVI)	G21
European Association for Cardiovascular Prevention & Rehabilitation (EACPR)	G22
European Association of Percutaneous Cardiovascular Interventions (EAPCI)	G23
European Heart Rhythm Association (EHRA)	G24
Heart Failure Association of the ESC (HFA)	G25
ESC Working Groups	G26
ESC Councils	G27
ESC Global Scientific Activities	G28
ESC Affiliated Cardiac Societies	G29
ESC Journal Family	G30
ESC Clinical Practice Guidelines	G31
ESC Education	G32
ESC EURObservational Research Programme	G33

General Information **G35**

Schedule	G36
Venue / Opening Hours / Inaugural Session	G37
Registration / Badges / CME Credits	G38
Press	G39
Public Transport / Cycle for your Heart	G40
Facilities and local information	G41
ESC TV	G42
ESC Congress 365	G43
ESC Congress resources	G44
Industry Information	G45

Scientific Programme **G51**

Best of ESC Congress 2013	G52
Congress Spotlight / Highlight Session	G53
General cardiology for Physicians, Nurses and Technicians	G54
Nursing and Allied Health Professionals Programme	G55
Cardiopulmonary Resuscitation (CPR) Workshops	G55
Science in Practice	G56
Basic Science	G57
A day with the Legends	G58
ESC Cardiologists of Tomorrow Track	G59
Experts Sessions	G61
ESC Cardiology Quiz	G62
ESC Clinical Practice Guidelines / Meet the Guidelines Task Force	G63
Guidelines into Practice	G65

Focus Imaging Intervention	G66
Focus Cardiology Practice	G67
Meet the Trialists	G68
Hot Line, Clinical Trial Update and Registry Sessions	G69
Joint Sessions with other organisations	G70
ESC Associations Track	G72
ESC Journals / The Lancet / European Commission.	G73
Cardiac Anatomy and Pathology Live Sessions	G73
Abstract Sessions.	G75
Posters (Village 9)	G76
Satellite symposia / Hands-On Tutorials / EBAC Accredited Educational Programmes	G78
Guidelines for Speakers	G79

Scientific Programme by Day and by Village

1

– Hands-On Tutorials	3
– Saturday 31 August	
Morning	18
Lunch	28
Afternoon	29
Afternoon Posters	34
– Sunday 1 September	
Morning	60
Morning Posters	82
Lunch	107
Afternoon	113
Afternoon Posters	135
Evening	160
– Monday 2 September	
Morning	164
Morning Posters	187
Lunch	211
Afternoon	216
Afternoon Posters	237
Evening	262
– Tuesday 3 September	
Morning	266
Morning Posters	287
Lunch	312
Afternoon	318
Afternoon Posters	322
– Wednesday 4 September	
Morning	348

Appendices

List of Chairpersons, Speakers and Authors	359
List of Topics	461
List of Acronyms	471
List of Exhibitors	481
List of Country Codes	499



Be part of the Community!

The European Society of Cardiology (ESC) represents more than 80,000 cardiology professionals from Europe and the rest of the world. Our mission is to reduce the burden of cardiovascular disease in Europe.

The ESC provides educational courses and certification, produces respected Clinical Practice Guidelines, edits and publishes leading journals, textbooks and other scientific publications, and it also oversees important registries and surveys.

The ESC Congress, our annual meeting, is the largest medical meeting in Europe. In collaboration with our

constituent bodies, we also organise several well-established subspecialty congresses throughout Europe.

Membership is possible through one of our 55 National Cardiac Societies, 6 Associations, 18 Working Groups, or 2 of our Councils, as well as through the distinguished community of Fellows of the ESC.

Joining the ESC will strengthen your position in the field of cardiology and open up a world of possibilities for sharing knowledge and experience, networking and advancing your career.

Come and join us at the ESC Stand

www.escardio.org



EUROPEAN
SOCIETY OF
CARDIOLOGY®

11:00–12:30 | Kiev - Village 2

HEART FAILURE: NEW MECHANISMS – NEW THERAPIES

Abstract Session

- Chairperson(s): J.L. Tamargo (Madrid, ES); S. Momomura (Saitama, JP)
- 11:00 **Long-term therapy with Bendavia (MTP-131), a novel mitochondria-targeting peptide, normalizes skeletal muscle fiber type composition in dogs with chronic heart failure.** 63
– H.N. Sabbah, S. Rastogi, R.C. Gupta, K. Zhang, M. Wang (Detroit, US)
- 11:15 **Mineralocorticoid receptor antagonists modulate ST2 signaling pathway in chronic heart failure.** 64
– M.C. Asensio-Lopez, J. Sanchez-Mas, D.A. Pascual-Figal, L. Caballero, M.J. Fernandez Del Palacio, G. Santarelli, S. Abenza, M.T. Perez-Martinez, M. Valdes-Chavarrri, A.M. Lax (Murcia, ES)
- 11:30 **Carvedilol sensitizes cardiac beta1-adrenergic receptors by increasing subsarcolemmal cAMP levels through ligand-induced dissociation of PDE4 from beta1-adrenergic receptors.** 65
– C. Maack, I. Lee, C. Molina, W. Richter, N. Wannemacher, A. Zimmer, E. Qvigstad, R. Fischmeister, M. Conti, M. Böhm (Homburg, DE; Chatenay-Malabry, FR; San Francisco, US; Oslo, NO)
- 11:45 **Pro-atrial natriuretic peptide1-126 is processed in the human circulation to a mature GC-A activating peptide with therapeutic potential in heart failure.** 66
– T. Ichiki, B.K. Huntley, S.M. Sandberg, S.J. Sangaralingham, I.A. Anderson, J.C. Burnett (Rochester, US)
- 12:00 **Galectin-3 as indicator of oxidative stress and inflammation in patients with chronic heart failure.** 67
– E.A. Medvedeva, Y.V. Shchukin, E.I. Seleznev, I.I. Berezin (Samara, RU)
- 12:15 **MIR-21 and miR-133 levels in peripheral blood mononuclear cells associate with left ventricular diastolic dysfunction in patients with diastolic heart failure.** 68
– M. Marketou, J. Kontarakis, E. Zacharis, F. Parthenakis, S. Margkoudakis, J. Logakis, P. Vardas (Heraklion, GR)

11:00–12:30 | Podgorica - Village 3

CONTROVERSIES IN ANTITHROMBOTIC THERAPY

Debate Session

- Chairperson(s): T.W. Weiss (Vienna, AT); D. Alexopoulos (Ekali, GR)
- Bivalirudin is the ideal anticoagulant in percutaneous coronary intervention for high-risk acute coronary syndrome.**
- 11:00 **Pro.** 69
– H.J. Rupprecht (Ruesselsheim, DE)
- 11:15 **Contra.** 70
– G. Montalescot (Paris, FR)
- Rebuttal.**
- 11:30 **Pro.** 71
– H.J. Rupprecht (Ruesselsheim, DE)
- 11:35 **Contra.** 72
– G. Montalescot (Paris, FR)
- 11:40 **Conclusion.**
- New oral anticoagulants are an important addition to dual antiplatelet therapy after acute coronary syndrome.**
- 11:45 **Pro.** 73
– C. Bode (Freiburg, DE)
- 12:00 **Contra.** 74
– S. Husted (Herning, DK)
- Rebuttal.**
- 12:15 **Pro.** 75
– C. Bode (Freiburg, DE)
- 12:20 **Contra.** 76
– S. Husted (Herning, DK)
- 12:25 **Conclusion.**

11:00–12:30 | Moscow - Village 3

WHAT IS NEW IN STENT THROMBOSIS?

Symposium

- Chairperson(s): R.F. Storey (Sheffield, GB); A. Kastrati (Munich, DE)
- 11:00 **High on-treatment platelet reactivity.** 77
– D. Trenk (Bad Krozingen, DE)
- 11:22 **Optimal duration of dual antiplatelet therapy.** 78
– J.M. Ten Berg (Nieuwegein, NL)
- 11:45 **The role of intravascular imaging.** 79
– G. Guagliumi (Bergamo, IT)
- 12:07 **Stent thrombosis in the new stent era.** 80
– C. Varenhorst (Uppsala, SE)

- Eicosapentaenoic acid restrains the development of the cardiovascular events independent of triglyceride and C-reactive protein reduction in Japanese hemodialysis patients.** P1428
 – M. Nasu, K. Seino, Y. Tamura, M. Suzuki, Y. Iwabuchi, N. Maeda, M. End, F. Yamauchi, M. Ohsawa (Morioka and Shiwa-gun, Yahabacho, JP)
- Anticoagulation management in atrial fibrillation: inter-country differences in Western Europe: data from the PREFER in AF registry.** P1429
 – J.-Y. Le Heuzey, B. Ammentorp, H. Darius, R. De Caterina, R.J. Schilling, J. Schmitt, J.L. Zamorano, P. Kirchhof (Paris, FR; Munich and Berlin, DE; Chieti, IT; London and Birmingham, GB; Madrid, ES)
- Effects of the direct thrombin inhibitor dabigatran etexilate vs warfarin on platelet function in patients with atrial fibrillation.** P1430
 – G. Renda, G. Malatesta, P. Lanuti, V. Bucciarelli, L. Candelori, L. Moretti, J. Van Ryn, M. Marchisio, S. Miscia, R. De Caterina (Chieti and Ascoli Piceno, IT; Biberach, DE)
- Differential effects of P2Y1 versus P2Y12 receptor antagonism on thrombosis and bleeding in rabbits.** P1431
 – P. Wong, E. Crain, C. Watson, W. Yang, R. Wexler, P. Lam, R. Rehfuess, W. Schumacher (Pennington, US)
- DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes (EDGE study).** P1432
 – H. Kihara, K. Nakamura, H. Oe, K. Shimada, S. Fukuda, K. Watanabe, T. Takagi, K. Hirata, J. Yoshikawa, H. Ito (Asahikawa, Okayama, Osaka, Kyoto, Wakayama and Nishinomiya, JP)
- Azelidipine versus diuretic against albuminuria used in combination with angiotensin receptor blocker in hypertensive patients with diabetes.** P1433
 – S. Tanaka, T. Sugiura, S. Yamashita, M. Kojima, Y. Dohi, K. Genjiro (Nagoya, Mie and Owariasahi, JP)
- Heart rate before ICU discharge: a simple and readily available predictor of short- and long-term mortality from critical illness.** P1434
 – W. Grandner, K.M. Muellauer, M.D. Duenser (Hall in Tyrol and Salzburg, AT)
- Hypertensive Crises in the Emergency department: true story or chasing the white rabbit? Prevalence and clinical picture in patients with severe elevations of arterial blood pressure.** P1435
 – G. Pepe, S. Contri, M. Castelli, A. Pavellini, P. Nazerian, P. Ticali, S. Vanni, S. Grifoni (Florence, IT)
- The difference of the influence of autonomic nervous activation caused by reactive hyperemia on two different endothelial function tests.** P1436
 – M. Yoshida, H. Tomiyama, K. Shiina, M. Odaira, A. Yamashina (Tokyo, JP)

STEM CELLS AND DEVELOPMENT

- Discussant(s): Stem cells dans development.** P1437
 – T. Brand (Harefield, GB), K. Fukuda (Tokyo, JP), J.L. Tamargo (Madrid, ES), J.A.C. Morais (Leiria, PT)
- Ventricular septal defects in mice targeted deletion of versican in vascular smooth muscle cells.** P1438
 – S. Hatano, S. Makino, H. Watanabe (Nagakute and Tokyo, JP)
- Role of the myeloid zinc finger protein 1 (Mzf1) in an Nkx2.5 enhancer positive cardiac progenitor cell population - modulation of cardiogenesis.** P1439
 – S. Doppler, M. Barz, H. Lahm, A. Werner, M.-A. Deutsch, M. Schiemann, S.M. Wu, R. Lange, M. Krane (Munich, DE; Stanford, US)
- Sinoatrial and atrioventricular node development: role of ROCK signalling.** P1440
 – R. Vicente Steijn, T.P. Kelder, L.J. Wisse, R.E. Poelmann, A.C. Gittenberger-De Groot, M.J. Schalij, M.R.M. Jongbloed (Leiden, NL)
- c-Myb regulate miR-143/145 expression in adult vascular smooth muscle cells and embryonic stem cell-derived.** P1441
 – O. El-Mounayri, M. Ishida, M. Husain (Toronto, CA; Na, JP)
- Physical lineage tracing of cells contributing to the chicken cardiac conduction system.** P1442
 – T.P. Kelder, R. Vicente Steijn, T. Harryvan, M.J. Schalij, M.C. De Ruiter, R.E. Poelmann, A.C. Gittenberger-De Groot, M.R.M. Jongbloed (Leiden, NL)
- Chick embryonic model of hypoplastic left heart syndrome: endocardial fibroelastosis.** P1443
 – D. Sedmera, T. Stopkova, Z. Pesevski (Prague, CZ)
- Glucocorticoids play a key role in maturation and structural organisation of the developing zebrafish cardiovascular system.** P1444
 – K.S. Wilson, G. Matrone, C.S. Tucker, J.J. Mullins, C.J. Kenyon, P.W.F. Hadoke, M.A. Denvir (Edinburgh, GB)
- Fetal echocardiography of a Vegf overexpression model shows impaired sino-atrial nodal function consistent with abnormal morphology.** P1445
 – E.E. Calkoen, N.H. Hahurij, R. Vicente-Steijn, C. Van Munsteren, A.C. Gittenberger-De Groot, M.J. Schalij, P. Steendijk, N.A. Blom, A.A. Roest, M.R.M. Jongbloed (Leiden, NL)
- Cell recruitment via the SDF1alpha/CXCR4 axis in hypertensive heart disease.** P1446
 – C. Sonntag, R. Schreckenberger, K.-D. Schlueter (Giessen, DE)
- TRAF6 regulates cardiomyocyte proliferation in zebrafish.** P1447
 – J. Seeger, E. Patzel, I. Berger, W. Rottbauer, S. Just (Ulm, DE)
- Re-trafficking of hERG reverses Long QT Syndrome 2 phenotype in human pluripotent stem cell derived cardiomyocytes.** P1448
Top Score Poster
 – A. Mehta, G.L. Sequiera, C.J.A. Ramachandra, Y. Sudiby, Y.Y. Chung, Y.W. Wong, T.H. Tan, R. Liew, P. Wong, W. Shim (Singapore, SG)
- The developmental origin of postnatal cardiac regeneration.** P1449
 – Y.-H. Liu, S.-H. Huang, Y.-S. Lin, H.-Y. Huang, L.-P. Lai, J.-L. Lin (New Taipei City and Taipei, TW)

16:30–18:00 | Warsaw - Village 7

NOVEL THERAPEUTIC INTERVENTIONS FOR HYPERTENSION

Clinical Seminar

- Chairperson(s): H. Krum (Melbourne, AU); P.S. Sever (London, GB)
- 16:30 **Renal denervation - ready for prime time?** 1995
– M. Böhm (Homburg/Saar, DE)
 - 16:52 **Novel baroreflex activation therapies.** 1996
– P.W. De Leeuw (Maastricht, NL)
 - 17:15 **New inhibitors of the mineralcorticoid axis.** 1997
– S. Taddei (Pisa, IT)
 - 17:37 **Renin and neutralendopeptidase inhibition - the end of the beginning or the beginning of the end?** 1998
– B. Williams (London, GB)

16:30–18:00 | Madrid - Village 7

MAKING SENSE OF CLINICAL TRIALS

Debate Session

- Chairperson(s): F. Zannad (Vandoeuvre-lès-Nancy, FR); S. Wassmann (Munich, DE)
- P values are dead!**
- 16:30 **Pro.** 1999
– P. Juni (Berne, CH)
 - 16:45 **Contra.** 2000
– S.J. Pocock (London, GB)
 - Rebuttal.**
 - 17:00 **Pro.** 2001
– P. Juni (Berne, CH)
 - 17:05 **Contra.** 2002
– S.J. Pocock (London, GB)
 - 17:10 **Conclusion.**
 - Subgroup analysis. Should they be discouraged?**
 - 17:15 **Pro.** 2003
– C. Torp-Pedersen (Hellerup, DK)
 - 17:30 **Contra.** 2004
– J.L. Tamargo (Madrid, ES)
 - Rebuttal.**
 - 17:45 **Pro.** 2005
– C. Torp-Pedersen (Hellerup, DK)
 - 17:50 **Contra.** 2006
– J.L. Tamargo (Madrid, ES)
 - 17:55 **Conclusion.**

16:30–18:00 | Bern - Village 7

A NEW LOOK AT THE MEASUREMENT OF BLOOD PRESSURE

Abstract Session

- Chairperson(s): E.V. Shlyakhto (St. Petersburg, RU); J. Dalal (Mumbai, IN)
- 16:30 **Ambulatory blood pressure monitoring improves risk stratification across JNC classes of conventional blood pressure evaluated in 7826 participants recruited from 11 populations.** 2007
– J. Brguljan Hitij, L. Thijs, Y. Li, T.W. Hansen, J. Boggia, K. Asayama, K. Bjorklund-Bodegard, K. Stolarz-Skrzypek, E. O'Brien, J. Staessen (Ljubljana, SI; Leuven, BE; Shanghai, CN; Gentofte, DK; Montevideo, UY; Uppsala, SE; Krakow, PL; Dublin, IE)
 - 16:45 **Relationship between wall-to-lumen ratio of retinal arterioles and clinic and 24 hours blood pressure.** 2008
– M.L. Muesan, C. Agabiti Rosei, A. Paini, M. Salvetti, C. Aggiusti, A. Cancarini, S. Duse, F. Semeraro, D. Rizzoni, E. Agabiti Rosei (Brescia, IT)
 - 17:00 **Obstructive sleep apnea and nocturnal hypertension are associated with concentric geometry and systolic dysfunction in patients with resistant hypertension. RESIST POL study.** 2009
– P. Dobrowolski, A. Klisiewicz, E. Florczak, A. Prejbisz, P. Sliwinski, P. Bielen, A. Januszewicz, J. Rybicka, P. Hoffman (Warsaw, PL)
 - 17:15 **Prognostic value of within-individual day-by-day variability of in-hospital blood pressure in sub-acute state of ischemic stroke: the Fukuoka stroke registry blood pressure variability study.** 2010 (W)
– K. Fukuda, H. Kai, M. Kamouchi, T. Imaizumi, T. Kitazono (Kurume and Fukuoka, JP)
 - 17:30 **Continuous positive airway pressure improves visit-to-visit blood pressure variability in patients with severe obstructive sleep apnea.** 2011
– K. Shiina, H. Tomiyama, Y. Takata, M. Odaira, M. Yoshida, Y. Nishihata, K. Kato, T. Yamaguchi, Y. Usui, A. Yamashina (Tokyo, JP)
 - 17:45 **Blood pressure variability parameters and the risk of developing hypertension in healthy young males: 5-year follow-up study.** 2012
– S. Tikhonova, V. Piskovatska (Odessa, UA)

- Retinal Arterio-Venule-Ratio (AVR) in the cardiovascular risk management of hypertension.** P5002
– S. Willikens, E. Zitron, E. Scholz, D. Scherer, C. Seyler, M. Waagelein, T. Kainowski, H. Katus, C. Karle, G. Duong (Budapest, HU; Heidelberg and Kuenzelsau, DE)
- Familial history of hypertension as a predictor of increased arterial stiffness.** P5003
– I. El Tebi, E. Baligh, H. Gamal, Z. Ashour, G. Youssef, A. Shahata, M. Mokhtar (Cairo, EG)
- The associations among vascular function, baroreceptor sensitivity, and their changes in hypertension.** P5004
– K. Kimura, H. Tomiyama, M. Odaira, M. Yoshida, K. Shiina, A. Yamashina (Saitama and Tokyo, JP)
- Early abnormalities of arterial distensibility in premenopausal women screened for stage 1 hypertension.** P5005
– C. Driussi, F. Saladini, L. Mos, O. Vriz, E. Benetti, P.F. Ballerini, S. Cozzio, G. Garavelli, E. Casiglia, P. Palatini (Udine, Padua, Vittorio Veneto and Trento, IT)
- Changes of central hemodynamics and pulse wave velocity after isometric handgrip exercise.** P5006
– S.-J. Joo, J.-H. Choi, S.-Y. Kim, K.-S. Kim (Jeju, KR)
- Unfavourable effect of androgen deficiency on aortic stiffness in hypertensive males at low and moderate cardiovascular risk.** P5007
– N. Ioakeimidis, C. Vlachopoulos, A. Aggelis, P. Xaplanteris, D. Terentes-Printzios, A. Aggelakas, M. Abdelrasoul, P. Pietri, G. Lazaros, C. Stefanadis (Athens, GR)
- The impact of high-normal blood pressure and hypertension on left ventricular function: a three-dimensional speckle tracking echocardiography study.** P5008
– M. Tadic, V.C. Celic, B.P. Pencic, A.M. Majstorovic, J.S. Suzic, A.S. Sljivic, B.I. Ivanovic, B.S. Stojcevic, S.B. Backovic, I.I. Ilic (Belgrade, RS)
- Low plasma testosterone and increased aortic stiffness: Importance of low-grade inflammation in hypertensive men.** P5009
– N. Ioakeimidis, C. Vlachopoulos, A. Aggelis, A. Aggelakas, K. Rokkas, M. Abdelrasoul, I. Iona, D. Terentes-Printzios, A. Synodinos, C. Stefanadis (Athens, GR)
- Higher blood pressure levels "plaque-in" carotid atherosclerosis.** P5010
– G. Moustakas, E. Chatzistamatiou, D. Papoutsis, D. Konstantinidis, I. Skiadas, S. Sideris, A. Androulakis, C. Avgeropoulou, I. Vlaseros, I. Kallikazaros (Athens, GR)
- Hypertensive patients with coronary artery disease exhibit increased carotid artery thermal heterogeneity.** P5011
– M. Drakopoulou, K. Toutouzias, G. Benetos, E. Tolis, A. Synetos, A. Michelongona, E. Tsiamis, H. Grassos, E. Siores, C.H. Stefanadis (Athens, GR; Bolton, GB)

CARDIAC PATHOPHYSIOLOGY

- Discussant(s): Cardiac pathophysiology.** P5012
– D.J.G.M. Duncker (Rotterdam, NL), M. Dorobantu (Bucharest, RO), H. Schunkert (Munich, DE)
- Pivotal involvement of IFN-gamma/Stat5 axis in compensatory cardiac hypertrophy induced by pressure overload.** P5013
– A. Kimura, Y. Ishida, M. Furuta, M. Nosaka, Y. Kuninaka, M. Kawaguchi, N. Mukaida, T. Kondo (Wakayama, Wakayama and Kanazawa, JP)
- Arrhythmogenic cardiomyopathy with reduction of connexin40 and altered ion channel expression due to an inactivation of cyclase-associated protein 2.** P5014
– F. Stoeckigt, V. Peche, A.A. Noegel, G. Nickenig, J.W. Schrickel (Bonn and Cologne, DE)
- TRPM4 channel re-expression after myocardial infarction is essential for survival in mice.** P5015
– M. Demion, M. Gueffier, J. Thireau, F. Aimond, M. Granier, Z. Khoueiry, P. Launay, J.L. Pasquie, S. Richard (Montpellier, Nîmes and Paris, FR)
- Impaired local regulation of ryanodine receptor type-2 by protein phosphatase 1 promotes atrial fibrillation.** P5016
– D.Y. Chiang, N. Li, G. Wang, Q. Wang, A. Quick, D. Skapura, X.H.T. Wehrens (Houston, US)
- A proteomic approach identifies myoferlin as a novel interacting partner of the cardiac sodium channel.** P5017
– S. Podliesna, R.F. Marsman, S. Piersma, M.L. Westerveld, C.R. Jimenez, P. Barnett, C.R. Bezzina (Amsterdam, NL)
- Ageing causes a progressive loss of L-type calcium current and a depression of the SR calcium content linked to lower SERCA2 and calsequestrin-2 expression in human atrial myocytes.** P5018
– A. Herraiz, J. Alvarez, C.E. Molina, A. Llach, J. Fernandes, A. Ferrero, J. Padro, J. Martinez-Gonzalez, J. Cinca, L. Hove-Madsen (Barcelona, ES)
- Human cardiac Kir2.1, but not Kir2.3, channel expression is regulated by Nav1.5.** P5019
– R. Caballero, M. Matamoros, M. Perez-Hernandez, P. Dolz-Gaiton, A. Barana, I. Amoros, M. Nunez, M. Gonzalez De La Fuente, J. Tamargo, E. Delpón (Madrid, ES)
- Loss of dihydrolipoylsuccinyltransferase (DLST) function leads to defective energy production and severe bradycardia in vivo.** P5020
– M. Kessler, I. Berger, S. Just, W. Rottbauer (Ulm, DE)
- Acetylcholine analogue mimics the protective effect of cardiac vagal nerve stimulation on ventricular fibrillation threshold.** P5021
– M. Kalla, M. Chotalia, G. Hao, D.J. Paterson, N. Herring (Oxford, GB)
- The electrocardiographic T-wave is mainly explained by temporal repolarization differences along various anatomical axes.** P5022
– V.M.F. Meijborg, C.E. Conrath, J.M.T. De Bakker, R. Coronel (Amsterdam, NL)
- Dronedarone-mediated antiarrhythmic but not inotropic effects depend on Na⁺/Ca²⁺ exchanger (NCX) activity: Investigations in NCX knockout and overexpressor mice.** P5023
– N. Boegeholz, K.B. Bauer, J.S. Schulte, P. Milberg, G. Moennig, W. Schmitz, L. Eckardt, F.U. Mueller, C. Pott (Münster, DE)